JAK2 and essential thrombocythemia: <i>Janus kinase 2</i> (<i>JAK2</i>) mutations are detected in 50-60% of ET and PMF, while <i>myeloproliferative leukemia</i> (<i>MPL</i>) virus oncogene mutations are present in 3-5% of cases.